Document:

EX-10.3

 Exhibit 10.3 

NALU MEDICAL, INC. 
 2014
EQUITY INCENTIVE PLAN 
 STOCK OPTION AGREEMENT 

Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined
meanings in this Stock Option Agreement (the “Option Agreement”). 
  

	I.	 NOTICE OF STOCK OPTION GRANT 

Name:                 «Name» 

Address:             «Address» 

                        
    «City_State_Zip» 
 The undersigned Participant (also referred to herein as Optionee) has been granted an
Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement, as follows: 
  

					
		 	Date of Grant:	  	 «Grant_Date»                                
                          
			
		 	Vesting Commencement Date:	  	 «Vest_Date»                                 
                           
			
		 	Exercise Price per Share:	  	 $«Price_Per_Share»                               
                 
			
		 	Total Number of Shares Granted:	  	 «Shares»                                 
                                 
			
		 	Total Exercise Price:	  	 $«Total_Price»                                
                        
			
		 	Type of Option:	  	 «ISO»       Incentive Stock Option
			
	 	 	 	  	 «NSO»     Nonstatutory Stock Option
			
		 	Term/Expiration Date:	  	 «Expire_Date»                                
                        

 Vesting Schedule: 

This Option shall be exercisable, in whole or in part, according to the following vesting schedule: 

[Twenty-five percent (25%) of the Shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement
Date, and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no
corresponding day, on the last day of the month), subject to Participant continuing to be a Service Provider through each such date.] 

 Termination Period: 

This Option shall be exercisable for three (3) months after Participant ceases to be a Service Provider, unless such termination is due to
Participant’s death or Disability, in which case this Option shall be exercisable for twelve (12) months after Participant ceases to be a Service Provider. Notwithstanding the foregoing sentence, in no event may this Option be exercised
after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 13 of the Plan. 
  

	II.	 AGREEMENT 

1. Grant of Option. The Administrator of the Company hereby grants to the Participant named in the Notice of Stock Option Grant in Part
I of this Agreement (“Participant”), an option (the “Option”) to purchase the number of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option Grant (the
“Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. Subject to Section 18 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this
Option Agreement, the terms and conditions of the Plan shall prevail. 
 If designated in the Notice of Stock Option Grant as an Incentive
Stock Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall
be treated as a Nonstatutory Stock Option (“NSO”). Further, if for any reason this Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as
a NSO granted under the Plan. In no event shall the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to
qualify for any reason as an ISO. 
 2. Exercise of Option. This Option shall be exercisable during its term in accordance with the
provisions of Section 6 of the Plan as follows: 
 (a) Right to Exercise.. This Option shall be exercisable during its term in
accordance with the Vesting Schedule set out in the Notice of Stock Option Grant and with the applicable provisions of the Plan and this Option Agreement. 

(b) Method of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A
(the “Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the
“Exercised Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any
applicable tax withholding, and an executed joinder agreement, in substantially the form attached hereto as Exhibit C, to the Company’s Amended and Restated Voting Agreement dated June 26, 2015 by and among the Company and the
stockholders listed on Exhibits A and B thereto, as may be amended from time to time. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price,
together with any applicable tax withholding. 

  
 -2- 

 No Shares shall be issued pursuant to the exercise of an Option unless such issuance and
such exercise comply with Applicable Laws. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to Participant on the date on which the Option is exercised with respect to such Shares. 

3. Participant’s Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended
(the “Securities Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise of all or any portion of this Option, deliver to the Company his or her Investment Representation
Statement in the form attached hereto as Exhibit B. 
 4. Lock-Up
Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of any Common Stock (or other securities) of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the
Company not to exceed one hundred and eighty (180) days following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested by the Company or the underwriters to
accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or
NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). 
 Participant agrees to execute and deliver such other
agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the
underwriters of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of
any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 4 shall not apply to a registration relating solely to employee benefit plans on
Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction
until the end of said one hundred and eighty (180) day (or other) period. Participant agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section 4. 

  
 -3- 

 5. Method of Payment. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Participant: 
 (a) cash; 

(b) check; 
 (c) consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or 
 (d) surrender of
other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of
the Administrator, shall not result in any adverse accounting consequences to the Company. 
 6. Restrictions on Exercise. This
Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation
of any Applicable Law. 
 7. Non-Transferability of Option. 

(a) This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised
during the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Participant. 

(b) Further, until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the
Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act
(the “Reliance End Date”), Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to persons who are “family members” (as defined in Rule 701(c)(3)
of the Securities Act) through gifts or domestic relations orders, or (ii) to an executor or guardian of Participant upon the death or disability of Participant. Until the Reliance End Date, the Options and, prior to exercise, the Shares
subject to this Option, may not be pledged, hypothecated or otherwise transferred or disposed of, including by entering into any short position, any “put equivalent position” or any “call equivalent position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as permitted in clauses (i) and (ii) of this paragraph. 

8. Term of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised
during such term only in accordance with the Plan and the terms of this Option Agreement. 
 9. Tax Obligations. 

(a) Tax Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or
retaining Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable to the Option exercise. Participant acknowledges and agrees that the Company may refuse to honor the
exercise and refuse to deliver the Shares if such withholding amounts are not delivered at the time of exercise. 

  
 -4- 

 (b) Notice of Disqualifying Disposition of ISO Shares. If the Option granted to
Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Date of Grant, or (ii) the date one
(1) year after the date of exercise, Participant shall immediately notify the Company in writing of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation income
recognized by Participant. 
 (c) Code Section 409A. Under Code Section 409A, an Option that vests after
December 31, 2004 (or that vested on or prior to such date but which was materially modified after October 3, 2004) that was granted with a per Share exercise price that is determined by the Internal Revenue Service (the “IRS”)
to be less than the Fair Market Value of a Share on the date of grant (a “discount option”) may be considered “deferred compensation.” An Option that is a “discount option” may result in (i) income recognition by
Participant prior to the exercise of the Option, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges. The “discount option” may also result in additional state income,
penalty and interest tax to the Participant. Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share on the
date of grant in a later examination. Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely
responsible for Participant’s costs related to such a determination. 
 10. Entire Agreement; Governing Law. The Plan is
incorporated herein by reference. The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and
Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and Participant. This Option Agreement is governed by the internal
substantive laws but not the choice of law rules of California. 
 11. No Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES
AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF
BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR
IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR
RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 

  
 -5- 

 Participant acknowledges receipt of a copy of the Plan and represents that he or she is
familiar with the terms and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Participant has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of
counsel prior to executing this Option and fully understands all provisions of the Option. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under
the Plan or this Option. Participant further agrees to notify the Company upon any change in the residence address indicated below. 
  

					
	PARTICIPANT	 		 	NALU MEDICAL, INC.
			
	   
	 		 	   

	Signature	 		 	By
			
	«Name»	 		 	   

	Print Name	 		 	 Print Name

			
	   
	 		 	   

		 		 	 Title

			
	   
	 		 	  

	Residence Address	 		 	
			
	   
	 		 	  

	Email	 		 	

  
 -6- 

 EXHIBIT A 

2014 Equity Incentive Plan 

EXERCISE NOTICE 
 Nalu Medical, Inc. 

1525 Faraday Avenue, Suite 180 
 Carlsbad, CA 92008 

Attention: President 
 1. Exercise of
Option. Effective as of today, ________________, ____, the undersigned (“Participant”) hereby elects to exercise Participant’s option (the “Option”) to purchase ________________ shares of the Common Stock (the
“Shares”) of Nalu Medical, Inc. (the “Company”) under and pursuant to the 2014 Equity Incentive Plan (the “Plan”) and the Stock Option Agreement dated «Grant_Date» (the “Option Agreement”). 

2. Delivery of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option
Agreement, and any and all withholding taxes due in connection with the exercise of the Option. 
 3. Representations of Participant.
Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. 

4. Rights as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a
duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall
be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as
provided in Section 13 of the Plan. 
 5. Company’s Right of First Refusal. Before any Shares held by Participant or any
transferee (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase
the Shares on the terms and conditions set forth in this Section 5 (the “Right of First Refusal”). 
 (a) Notice of
Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each
proposed purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to
transfer the Shares (the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s). 

 (b) Exercise of Right of First Refusal. At any time within thirty (30) days
after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at
the purchase price determined in accordance with subsection (c) below. 
 (c) Purchase Price. The purchase price (“Purchase
Price”) for the Shares purchased by the Company or its assignee(s) under this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith. 
 (d)
Payment. Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of
repurchase by an assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the Notice. 

(e) Holder’s Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are
not purchased by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or
other transfer is consummated within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in
writing that the provisions of this Section 5 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new Notice
shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 

(f) Exception for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of
any or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt
from the provisions of this Section 5. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the
Shares so transferred subject to the provisions of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5. 

(g) Termination of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the
first sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded. 

  
 -2- 

 6. Tax Consultation. Participant understands that Participant may suffer adverse tax
consequences as a result of Participant’s purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the
Shares and that Participant is not relying on the Company for any tax advice. 
 7. Restrictive Legends and Stop-Transfer Orders.

 (a) Legends. Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially
equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws: 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD
OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
THEREWITH. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY
THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST
REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR
A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY
THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER. 
 (b) Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers
its own securities, it may make appropriate notations to the same effect in its own records. 
 (c) Refusal to Transfer. The
Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the
right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

  
 -3- 

 8. Successors and Assigns. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon
Participant and his or her heirs, executors, administrators, successors and assigns. 
 9. Interpretation. Any dispute regarding the
interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall be
final and binding on all parties. 
 10. Governing Law; Severability. This Exercise Notice is governed by the internal substantive
laws, but not the choice of law rules, of California. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice shall continue in full force and
effect. 
 11. Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan,
the Option Agreement, Investment Representation Statement and the Joinder Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the
Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and Participant. 

 

									
	Submitted by:	 		 	Accepted by:
			
	PARTICIPANT	 		 	NALU MEDICAL, INC.
			
	 	 		 	 
	Signature	 		 	By
			
	«Name»	 		 	 
	Print Name	 		 	Print Name
			
		 		 	 
		 		 	Title
			
	Address:	 		 	Address:
			
	 	 		 	 
			
	 	 		 	 
			
	 	 		 	 
	Email	 		 	Date Received

  
 -4- 

 EXHIBIT B 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	PARTICIPANT	  	:	  	«NAME»
			
	COMPANY	  	:	  	NALU MEDICAL, INC.
			
	SECURITY	  	:	  	COMMON STOCK
			
	AMOUNT	  	:	  	
			
	DATE	  	:	  	

 In connection with the purchase of the above-listed Securities, the undersigned Participant represents to the Company the
following: 
 (a) Participant is aware of the Company’s business affairs and financial condition and has acquired sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s own account only and not with a view to, or for resale in connection with,
any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 
 (b)
Participant acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption
depends upon, among other things, the bona fide nature of Participant’s investment intent as expressed herein. In this connection, Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such
exemption may be unavailable if Participant’s representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an
increase or decrease in the market price of the Securities, or for a period of one (1) year or any other fixed period in the future. Participant further understands that the Securities must be held indefinitely unless they are subsequently
registered under the Securities Act or an exemption from such registration is available. Participant further acknowledges and understands that the Company is under no obligation to register the Securities. Participant understands that the
certificate evidencing the Securities shall be imprinted with any legend required under applicable state securities laws. 
 (c) Participant
is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer
thereof, in a non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the Option to
Participant, the exercise shall be exempt from registration under the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days
thereafter (or such 

 
longer period as any market stand-off agreement may require) the Securities exempt under Rule 701 may be resold, subject to the satisfaction of the
applicable conditions specified by Rule 144, including in the case of affiliates (1) the availability of certain public information about the Company, (2) the amount of Securities being sold during any three (3) month period not
exceeding specified limitations, (3) the resale being made in an unsolicited “broker’s transaction”, transactions directly with a “market maker” or “riskless principal transactions” (as those terms are defined
under the Securities Exchange Act of 1934) and (4) the timely filing of a Form 144, if applicable. 
 In the event that the
Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule 144, which may require (i) the availability of current
public information about the Company; (ii) the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule 144) for the Securities; and (iii) in the case of the sale of Securities by an
affiliate, the satisfaction of the conditions set forth in sections (2), (3) and (4) of the paragraph immediately above. 
 (d)
Participant further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption shall be
required; and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a
registered offering and otherwise than pursuant to Rules 144 or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective
brokers who participate in such transactions do so at their own risk. Participant understands that no assurances can be given that any such other registration exemption shall be available in such event. 

 

			
	PARTICIPANT
	
	 
	Signature
	
	«Name»
	Print Name
	
	 
	Date

  
 -2- 

 EXHIBIT C 

JOINDER AGREEMENT 

WHEREAS, Nalu Medical, Inc. (the “Company”) previously granted the undersigned (the “Exercising Participant”) a stock
option (the “Option”) to purchase shares of the Company’s common stock (“Common Stock”) under the Company’s 2014 Equity Incentive Plan and subject to the terms and conditions of a Stock Option Agreement (the “Stock
Option Agreement”). 
 WHEREAS, the Exercising Participant now wishes to exercise the Option in accordance with the terms of the Stock
Option Agreement. 
 NOW, THEREFORE, by execution of this Joinder Agreement, the Exercising Participant hereby acknowledges and agrees as
follows: 
  

	 	1.	 The Exercising Participant hereby acknowledges receipt of the Company’s Amended and Restated Voting
Agreement dated June 26, 2015 by and among the Company and the stockholders listed on Exhibits A and B thereto, as may be amended from time to time (the “Voting Agreement”) and represents to the Company that he or she has read and
fully understands such Voting Agreement. 

  

	 	2.	 The Exercising Participant (i) has had an opportunity to consult with counsel and other advisors before
entering into this Joinder Agreement, (ii) hereby adopts and agrees to be bound by Section 3.1 of the Voting Agreement as a Common Holder (as defined in the Voting Agreement), and (iii) authorizes the Company to attach this executed
Joinder Agreement to the Voting Agreement, and to take such other actions as may be necessary or desirable to bind the Exercising Participant to such provisions. 

 

	 	3.	 The Exercising Participant has all requisite power and authority to enter into this Joinder Agreement and to
carry out his or her obligations hereunder. 

  

	 	4.	 All notices provided to the Exercising Participant shall be sent or delivered to the following address:

  

							
		  	     

 
	  	
		  	     

 
	  	
				
		  	Facsimile:	  	 	  	
				
		  	e-mail:	  	 	  	

  

	 	5.	 Governing Law. This Joinder Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware applicable to contracts made and to be performed entirely within such state. 

 IN WITNESS WHEREOF, the Exercising Participant has executed and delivered this Joinder
Agreement. 
  

					
	EXERCISING PARTICIPANT	 		 	NALU MEDICAL, INC.
			
	   
	 		 	   

	Signature	 		 	By
			
	«NAME»	 		 	   

	Print Name	 		 	Print Name
			
	   
	 		 	   

		 		 	Title
			
	   
	 		 	  

	Residence Address	 		 	
			
	   
	 		 	  

	Email Address	 		 	
			
	Dated: _______________________________, _____________	 		 	  

  
 -2- 

 NALU MEDICAL, INC. 

2014 EQUITY INCENTIVE PLAN 

STOCK OPTION AGREEMENT — EARLY EXERCISE 

Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined
meanings in this Stock Option Agreement – Early Exercise (the “Option Agreement”). 
  

	I.	 NOTICE OF STOCK OPTION GRANT 

 

					
		 	Name:	  	«Name»
			
		 	Address:	  	«Address»
		 		  	«City_State_Zip»

 The undersigned Participant (also referred to herein as Optionee) has been granted an Option to purchase
Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement, as follows: 
  

									
				
		 	Date of Grant:	  	«Grant_Date»	  	
				
		 	Vesting Commencement Date:	  	«Vest_Date»	  	
				
		 	Exercise Price per Share:	  	$«Price_Per_Share»	  	
				
		 	Total Number of Shares Granted:	  	«Shares»	  	
				
		 	Total Exercise Price:	  	$«Total_Price»	  	
					
		 	Type of Option:	  	«ISO»	  	Incentive Stock Option	  	
					
	 	 	 	  	«NSO»	  	Nonstatutory Stock Option	  	 
				
		 	Term/Expiration Date:	  	«Expire_Date»	  	

 Vesting Schedule: 

This Option shall be exercisable, in whole or in part, according to the following vesting schedule: 

[Twenty-five percent (25%) of the Shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement
Date, and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no
corresponding day, on the last day of the month), subject to Participant continuing to be a Service Provider through each such date.] 

  
 -3- 

 Termination Period: 

This Option shall be exercisable for three (3) months after Participant ceases to be a Service Provider, unless such termination is due to
Participant’s death or Disability, in which case this Option shall be exercisable for twelve (12) months after Participant ceases to be a Service Provider. Notwithstanding the foregoing sentence, in no event may this Option be exercised
after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 13 of the Plan. 
  

	II.	 AGREEMENT 

12. Grant of Option. The Administrator of the Company hereby grants to the Participant named in the Notice of Stock Option Grant in Part
I of this Agreement (“Participant”), an option (the “Option”) to purchase the number of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option Grant (the
“Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. Subject to Section 18 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this
Option Agreement, the terms and conditions of the Plan shall prevail. 
 If designated in the Notice of Stock Option Grant as an Incentive
Stock Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall
be treated as a Nonstatutory Stock Option (“NSO”). Further, if for any reason this Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as
a NSO granted under the Plan. In no event shall the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to
qualify for any reason as an ISO. 
 13. Exercise of Option. This Option shall be exercisable during its term in accordance with the
provisions of Section 6 of the Plan as follows: 
 (a) Right to Exercise. 

(i) Subject to subsections 2(a)(ii) and 2(a)(iii) below, this Option shall be exercisable cumulatively according to the vesting schedule
set forth in the Notice of Stock Option Grant. Alternatively, at the election of Participant, this Option may be exercised in whole or in part at any time as to Shares that have not yet vested. Vested Shares shall not be subject to the
Company’s repurchase right (as set forth in the Restricted Stock Purchase Agreement, attached hereto as Exhibit C-1). 

(ii) As a condition to exercising this Option for unvested Shares, Participant shall execute the Restricted Stock Purchase Agreement. 

(iii) This Option may not be exercised for a fraction of a Share. 

  
 -4- 

 (b) Method of Exercise. This Option shall be exercisable by delivery of an exercise
notice in the form attached as Exhibit A (the “Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to exercise the Option, the number of Shares with
respect to which the Option is being exercised (the “Exercised Shares”), and such other representations and agreements as may be required by the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price
as to all Exercised Shares, together with any applicable tax withholding, and an executed joinder agreement, in substantially the form attached hereto as Exhibit D, to the Company’s Amended and Restated Voting Agreement dated
June 26, 2015 by and among the Company and the stockholders listed on Exhibits A and B thereto, as may be amended from time to time. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice
accompanied by the aggregate Exercise Price, together with any applicable tax withholding. 
 No Shares shall be issued pursuant to the
exercise of an Option unless such issuance and such exercise comply with Applicable Laws. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to Participant on the date on which the Option is exercised with
respect to such Shares. 
 14. Participant’s Representations. In the event the Shares have not been registered under the
Securities Act of 1933, as amended (the “Securities Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise of all or any portion of this Option, deliver to the Company his
or her Investment Representation Statement in the form attached hereto as Exhibit B. 
 15. Lock-Up Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in
part, any of the economic consequences of ownership of any Common Stock (or other securities) of the Company held by Participant (other than those included in the registration) for a period specified by the representative of the underwriters of
Common Stock (or other securities) of the Company not to exceed one hundred and eighty (180) days following the effective date of any registration statement of the Company filed under the Securities Act (or such other period as may be requested
by the Company or the underwriters to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). 
 Participant
agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the
Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Participant shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative
in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section 4 shall not apply to a registration
relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a
Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period. Participant agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this
Section 4. 

  
 -5- 

 16. Method of Payment. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Participant: 
 (a) cash; 

(b) check; 
 (c) consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or 
 (d) surrender of
other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of
the Administrator, shall not result in any adverse accounting consequences to the Company. 
 17. Restrictions on Exercise. This
Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation
of any Applicable Law. 
 18. Non-Transferability of Option. 

(a) This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised
during the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Participant. 

(b) Further, until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the
Administrator determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the Exchange Act as set forth in Rule 12h-1(f) promulgated under the Exchange Act
(the “Reliance End Date”), Participant shall not transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to persons who are “family members” (as defined in Rule 701(c)(3)
of the Securities Act) through gifts or domestic relations orders, or (ii) to an executor or guardian of Participant upon the death or disability of Participant. Until the Reliance End Date, the Options and, prior to exercise, the Shares
subject to this Option, may not be pledged, hypothecated or otherwise transferred or disposed of, including by entering into any short position, any “put equivalent position” or any “call equivalent position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as permitted in clauses (i) and (ii) of this paragraph. 

19. Term of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised
during such term only in accordance with the Plan and the terms of this Option Agreement. 

  
 -6- 

 20. Tax Obligations. 

(a) Tax Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing or
retaining Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable to the Option exercise. Participant acknowledges and agrees that the Company may refuse to honor the
exercise and refuse to deliver the Shares if such withholding amounts are not delivered at the time of exercise. 
 (b) Notice of
Disqualifying Disposition of ISO Shares. If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two
(2) years after the Date of Grant, or (ii) the date one (1) year after the date of exercise, Participant shall immediately notify the Company in writing of such disposition. Participant agrees that Participant may be subject to income
tax withholding by the Company on the compensation income recognized by Participant. 
 (c) Code Section 409A.
Under Code Section 409A, an Option that vests after December 31, 2004 (or that vested on or prior to such date but which was materially modified after October 3, 2004) that was granted with a per Share exercise price that is
determined by the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on the date of grant (a “discount option”) may be considered “deferred compensation.” An Option that is a
“discount option” may result in (i) income recognition by Participant prior to the exercise of the Option, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges. The
“discount option” may also result in additional state income, penalty and interest tax to the Participant. Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of
this Option equals or exceeds the Fair Market Value of a Share on the date of grant in a later examination. Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the Fair Market
Value of a Share on the date of grant, Participant shall be solely responsible for Participant’s costs related to such a determination. 

21. Entire Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the
entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified
adversely to the Participant’s interest except by means of a writing signed by the Company and Participant. This Option Agreement is governed by the internal substantive laws but not the choice of law rules of California. 

22. No Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE
HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER.
PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO 

  
 -7- 

 
NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH
PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 

Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and
hereby accepts this Option subject to all of the terms and provisions thereof. Participant has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully
understands all provisions of the Option. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. Participant further agrees
to notify the Company upon any change in the residence address indicated below. 
  

					
	 PARTICIPANT
	 		 	NALU MEDICAL, INC.
			
	   
	 		 	   

	Signature	 		 	By
			
	   
	 		 	   

	Print Name	 		 	Print Name
			
	   
	 		 	   

		 		 	Title
			
	   
	 		 	  

	Residence Address	 		 	
			
	   
	 		 	  

	Email Address	 		 	

  
 -8- 

 EXHIBIT A 

2014 Equity Incentive Plan 

EXERCISE NOTICE 
 Nalu Medical, Inc. 

1525 Faraday Avenue, Suite 180 
 Carlsbad, CA 92008 

Attention: President 
 12. Exercise of
Option. Effective as of today, ________________, ____, the undersigned (“Participant”) hereby elects to exercise Participant’s option (the “Option”) to purchase ________________ shares of the Common Stock (the
“Shares”) of Nalu Medical, Inc. (the “Company”) under and pursuant to the 2014 Equity Incentive Plan (the “Plan”) and the Stock Option Agreement – Early Exercise dated «Grant_Date» (the “Option
Agreement”). 
 13. Delivery of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as
set forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option. 
 14.
Representations of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. 

15. Rights as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a
duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall
be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as
provided in Section 13 of the Plan. 
 16. Company’s Right of First Refusal. Before any Shares held by Participant or any
transferee (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase
the Shares on the terms and conditions set forth in this Section 5 (the “Right of First Refusal”). 
 (a) Notice of
Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each
proposed purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to
transfer the Shares (the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s). 

 (b) Exercise of Right of First Refusal. At any time within thirty (30) days
after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at
the purchase price determined in accordance with subsection (c) below. 
 (c) Purchase Price. The purchase price (“Purchase
Price”) for the Shares purchased by the Company or its assignee(s) under this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith. 
 (d)
Payment. Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of
repurchase by an assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the Notice. 

(e) Holder’s Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are
not purchased by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or
other transfer is consummated within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in
writing that the provisions of this Section 5 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new Notice
shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 

(f) Exception for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of
any or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt
from the provisions of this Section 5. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the
Shares so transferred subject to the provisions of this Section 5, and there shall be no further transfer of such Shares except in accordance with the terms of this Section 5. 

(g) Termination of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the
first sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded. 

17. Tax Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s
purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with the purchase or disposition of the Shares and that Participant is not relying on the
Company for any tax advice. 

  
 -2- 

 18. Restrictive Legends and Stop-Transfer Orders. 

(a) Legends. Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially
equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws: 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD
OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
THEREWITH. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY
THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST
REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR
A PERIOD OF TIME FOLLOWING THE EFFECTIVE DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY
THE HOLDER PRIOR TO THE EXPIRATION OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER. 
 (b) Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers
its own securities, it may make appropriate notations to the same effect in its own records. 
 (c) Refusal to Transfer. The
Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the
right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

  
 -3- 

 19. Successors and Assigns. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon
Participant and his or her heirs, executors, administrators, successors and assigns. 
 20. Interpretation. Any dispute regarding the
interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall be
final and binding on all parties. 
 21. Governing Law; Severability. This Exercise Notice is governed by the internal substantive
laws, but not the choice of law rules, of California. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice shall continue in full force and
effect. 
 22. Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan,
the Restricted Stock Purchase Agreement, the Option Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings
and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and Participant. 

 

							
	Submitted by:	 		 	Accepted by:
	PARTICIPANT	 		 	NALU MEDICAL, INC.
				
	 	 		 		 	 
	Signature	 		 		 	By
	 	 		 		 	 
	Print Name	 		 		 	Print Name
		 		 		 	 
		 		 		 	 Title

		 		 		 	
	Address:	 		 		 	Address:
		 		 		 	
	 			 
		 		 		 	
	 			 
		 		 		 	
	Email	 		 		 	Date Received

  
 -4- 

 EXHIBIT B 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	PARTICIPANT	  	:	  	
	COMPANY	  	:	  	NALU MEDICAL, INC.
	SECURITY	  	:	  	COMMON STOCK
	AMOUNT	  	:	  	
	DATE	  	:	  	

 In connection with the purchase of the above-listed Securities, the undersigned Participant represents to the Company the
following: 
 (e) Participant is aware of the Company’s business affairs and financial condition and has acquired sufficient
information about the Company to reach an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s own account only and not with a view to, or for resale in
connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 

(f) Participant acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and
have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant’s investment intent as expressed herein. In this
connection, Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s representation was predicated solely upon a present intention to hold
these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one (1) year or any other fixed period in
the future. Participant further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further acknowledges and
understands that the Company is under no obligation to register the Securities. Participant understands that the certificate evidencing the Securities shall be imprinted with any legend required under applicable state securities laws. 

(g) Participant is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in
substance, permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain
conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the Option to Participant, the exercise shall be exempt from registration under the Securities Act. In the event the Company becomes
subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days thereafter (or such 

 
longer period as any market stand-off agreement may require) the Securities exempt under Rule 701 may be resold, subject to the satisfaction of the
applicable conditions specified by Rule 144, including in the case of affiliates (1) the availability of certain public information about the Company, (2) the amount of Securities being sold during any three (3) month period not
exceeding specified limitations, (3) the resale being made in an unsolicited “broker’s transaction”, transactions directly with a “market maker” or “riskless principal transactions” (as those terms are defined
under the Securities Exchange Act of 1934) and (4) the timely filing of a Form 144, if applicable. 
 In the event that the
Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule 144, which may require (i) the availability of current
public information about the Company; (ii) the resale to occur more than a specified period after the purchase and full payment (within the meaning of Rule 144) for the Securities; and (iii) in the case of the sale of Securities by an
affiliate, the satisfaction of the conditions set forth in sections (2), (3) and (4) of the paragraph immediately above. 
 (h)
Participant further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption shall be
required; and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a
registered offering and otherwise than pursuant to Rules 144 or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective
brokers who participate in such transactions do so at their own risk. Participant understands that no assurances can be given that any such other registration exemption shall be available in such event. 

 

	
	 PARTICIPANT
  

	
	
	Signature
	
	 
	Print Name
	
	 
	Date

  
 -2- 

 EXHIBIT C-1 

NALU MEDICAL, INC. 
 2014
EQUITY INCENTIVE PLAN 
 RESTRICTED STOCK PURCHASE AGREEMENT 

THIS RESTRICTED STOCK PURCHASE AGREEMENT (the “Agreement”) is made between _____________________________ (the “Purchaser”)
and Nalu Medical, Inc. (the “Company”) or its assignees of rights hereunder as of __________________, ____. 
 Unless otherwise
defined herein, the terms defined in the 2014 Equity Incentive Plan shall have the same defined meanings in this Agreement. 
 RECITALS

 A. Pursuant to the exercise of the option granted to Purchaser under the Plan and pursuant to the Stock Option Agreement – Early
Exercise (the “Option Agreement”) dated «Grant_Date» by and between the Company and Purchaser with respect to such grant (the “Option”), which Plan and Option Agreement are hereby incorporated by reference, Purchaser
has elected to purchase _________ of those shares of Common Stock which have not become vested under the vesting schedule set forth in the Option Agreement (“Unvested Shares”). The Unvested Shares and the shares subject to the Option
Agreement, which have become vested are sometimes collectively referred to herein as the “Shares.” 
 B. As required by the Option
Agreement, as a condition to Purchaser’s election to exercise the option, Purchaser must execute this Agreement, which sets forth the rights and obligations of the parties with respect to Shares acquired upon exercise of the Option. 

1. Repurchase Option. 

(a) If Purchaser’s status as a Service Provider is terminated for any reason, including for death and Disability, the Company shall have
the right and option for ninety (90) days from such date to purchase from Purchaser, or Purchaser’s personal representative, as the case may be, all of the Purchaser’s Unvested Shares as of the date of such termination at the price
paid by the Purchaser for such Shares (the “Repurchase Option”). 
 (b) Upon the occurrence of such termination, the Company may
exercise its Repurchase Option by delivering personally or by registered mail, to Purchaser (or his or her transferee or legal representative, as the case may be) with a copy to the escrow agent described in Section 2 below, a notice in writing
indicating the Company’s intention to exercise the Repurchase Option AND, at the Company’s option, (i) by delivering to the Purchaser (or the Purchaser’s transferee or legal representative) a check in the amount of the aggregate
repurchase price, or (ii) by the Company canceling an amount of the Purchaser’s indebtedness to the Company equal to the aggregate repurchase price, or (iii) by a combination of (i) and (ii) so that the combined payment and

 
cancellation of indebtedness equals such aggregate repurchase price. Upon delivery of such notice and payment of the aggregate repurchase price in any of the ways described above, the Company
shall become the legal and beneficial owner of the Unvested Shares being repurchased and the rights and interests therein or relating thereto, and the Company shall have the right to retain and transfer to its own name the number of Unvested Shares
being repurchased by the Company. 
 (c) Whenever the Company shall have the right to repurchase Unvested Shares hereunder, the Company may
designate and assign one or more employees, officers, directors or stockholders of the Company or other persons or organizations to exercise all or a part of the Company’s Repurchase Option under this Agreement and purchase all or a part of
such Unvested Shares. 
 (d) If the Company does not elect to exercise the Repurchase Option conferred above by giving the requisite notice
within ninety (90) days following the termination, the Repurchase Option shall terminate. 
 (e) The Repurchase Option shall terminate
in accordance with the vesting schedule contained in Purchaser’s Option Agreement. 
 2. Transferability of the Shares; Escrow.

 (a) Purchaser hereby authorizes and directs the Secretary of the Company, or such other person designated by the Company, to transfer the
Unvested Shares as to which the Repurchase Option has been exercised from Purchaser to the Company. 
 (b) To insure the availability for
delivery of Purchaser’s Unvested Shares upon repurchase by the Company pursuant to the Repurchase Option under Section 1, Purchaser hereby appoints the Secretary, or any other person designated by the Company as escrow agent (the
“Escrow Agent”), as its attorney-in-fact to sell, assign and transfer unto the Company, such Unvested Shares, if any, repurchased by the Company pursuant to
the Repurchase Option and shall, upon execution of this Agreement, deliver and deposit with the Escrow Agent, the share certificates representing the Unvested Shares, together with the stock assignment duly endorsed in blank, attached hereto as
Exhibit C-2. The Unvested Shares and stock assignment shall be held by the Escrow Agent in escrow, pursuant to the Joint Escrow Instructions of the Company and Purchaser attached as Exhibit C-3 hereto, until the Company exercises its Repurchase Option, until such Unvested Shares are vested, or until such time as this Agreement no longer is in effect. Upon vesting of the Unvested Shares, the Escrow
Agent shall promptly deliver to the Purchaser the certificate or certificates representing such Shares in the Escrow Agent’s possession belonging to the Purchaser, and the Escrow Agent shall be discharged of all further obligations hereunder;
provided, however, that the Escrow Agent shall nevertheless retain such certificate or certificates as Escrow Agent if so required pursuant to other restrictions imposed pursuant to this Agreement. 

(c) Neither the Company nor the Escrow Agent shall be liable for any act it may do or omit to do with respect to holding the Shares in escrow
and while acting in good faith and in the exercise of its judgment. 
 (d) Transfer or sale of the Shares is subject to restrictions on
transfer imposed by any applicable state and federal securities laws. Any transferee shall hold such Shares subject to all the provisions hereof and the Exercise Notice executed by the Purchaser with respect to any Unvested Shares purchased by
Purchaser and shall acknowledge the same by signing a copy of this Agreement. 

  
 -2- 

 3. Ownership, Voting Rights, Duties. This Agreement shall not affect in any way the
ownership, voting rights or other rights or duties of Purchaser, except as specifically provided herein. 
 4. Legends. The share
certificate evidencing the Shares issued hereunder shall be endorsed with the following legend (in addition to any legend required under applicable federal and state securities laws): 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS UPON TRANSFER AND RIGHTS OF REPURCHASE AS SET FORTH IN AN
AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 5. Adjustment for
Stock Split. All references to the number of Shares and the purchase price of the Shares in this Agreement shall be appropriately adjusted to reflect any stock split, stock dividend or other change in the Shares, which may be made by the Company
pursuant to Section 13 of the Plan after the date of this Agreement. 
 6. Notices. Notices required hereunder shall be given in
person or by registered mail to the address of Purchaser shown on the records of the Company, and to the Company at their respective principal executive offices. 

7. Survival of Terms. This Agreement shall apply to and bind Purchaser and the Company and their respective permitted assignees and
transferees, heirs, legatees, executors, administrators and legal successors. 
 8. Section 83(b) Election. Purchaser hereby
acknowledges that he or she has been informed that, with respect to the exercise of an Option for Unvested Shares, an election (the “Election”) may be filed by the Purchaser with the Internal Revenue Service, within thirty (30) days
of the purchase of the exercised Shares, electing pursuant to Section 83(b) of the Code to be taxed currently on any difference between the purchase price of the exercised Shares and their Fair Market Value on the date of purchase. In the case
of a Nonstatutory Stock Option, this will result in the recognition of taxable income to the Purchaser on the date of exercise, measured by the excess, if any, of the Fair Market Value of the exercised Shares, at the time the Option is exercised
over the purchase price for the exercised Shares. Absent such an Election, taxable income will be measured and recognized by Purchaser at the time or times on which the Company’s Repurchase Option lapses. In the case of an Incentive Stock
Option, such an Election will result in a recognition of income to the Purchaser for alternative minimum tax purposes on the date of exercise, measured by the excess, if any, of the Fair Market Value of the exercised Shares, at the time the option
is exercised, over the purchase price for the exercised Shares. Absent such an Election, alternative minimum taxable income will be measured and recognized by Purchaser at the time or times on which the Company’s Repurchase Option lapses. 

  
 -3- 

 This discussion is intended only as a summary of the general United States income tax laws
that apply to exercising Options as to Shares that have not yet vested and is accurate only as of the date this form Agreement was approved by the Board. The federal, state and local tax consequences to any particular taxpayer will depend upon his
or her individual circumstances. Purchaser is strongly encouraged to seek the advice of his or her own tax consultants in connection with the purchase of the Shares and the advisability of filing of the Election under Section 83(b) of the Code.
A form of Election under Section 83(b) is attached hereto as Exhibit C-4 for reference. 

PURCHASER ACKNOWLEDGES THAT IT IS PURCHASER’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY THE ELECTION UNDER
SECTION 83(b) OF THE CODE, EVEN IF PURCHASER REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON PURCHASER’S BEHALF. 

9. Representations. Purchaser has reviewed with his or her own tax advisors the federal, state, local and foreign tax consequences of
this investment and the transactions contemplated by this Agreement. Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. Purchaser understands that he or she (and not the
Company) shall be responsible for his or her own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 

10. Entire Agreement; Governing Law. The Plan and Option Agreement are incorporated herein by reference. The Plan, the Option
Agreement, the Exercise Notice, this Agreement, and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and
agreements of the Company and Purchaser with respect to the subject matter hereof, and may not be modified adversely to the Purchaser’s interest except by means of a writing signed by the Company and Purchaser. This Agreement is governed by the
internal substantive laws but not the choice of law rules of California. 

  
 -4- 

 Purchaser represents that he or she has read this Agreement and is familiar with its terms
and provisions. Purchaser hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board upon any questions arising under this Agreement. 

IN WITNESS WHEREOF, this Agreement is deemed made as of the date first set forth above. 

 

							
	PARTICIPANT	 		 	NALU MEDICAL, INC.
				
		 		 		 	 
	Signature	 		 		 	By
		 		 		 	
	Print Name	 		 		 	Print Name
		 		 		 	
	 	 		 		 	Title
		 		 		 	
	 Residence Address
	 		 		 	
		 		 		 	
	 Email Address
	 		 		 	

 Dated: _________________________,          

  
 -5- 

 EXHIBIT C-2 

ASSIGNMENT SEPARATE FROM CERTIFICATE 
 FOR
VALUE RECEIVED I, __________________________, hereby sell, assign and transfer unto Nalu Medical, Inc. _____________ shares of the Common Stock of Nalu Medical, Inc. standing in my name of the books of said corporation represented by Certificate
No. _____ herewith and do hereby irrevocably constitute and appoint __________________________ to transfer the said stock on the books of the within named corporation with full power of substitution in the premises. 

This Stock Assignment may be used only in accordance with the Restricted Stock Purchase Agreement between Nalu Medical, Inc. and the undersigned dated
______________, _____ (the “Agreement”). 
  

									
	Dated:	 	_________________________,        	 		 	Signature:	 	 
		 		 		 		 	
		 		 		 		 	

 INSTRUCTIONS: Please do not fill in any blanks other than the signature line. The purpose of this assignment
is to enable the Company to exercise its “repurchase option,” as set forth in the Agreement, without requiring additional signatures on the part of the Purchaser. 

 EXHIBIT C-3 

JOINT ESCROW INSTRUCTIONS 

_________________, ____ 
 Nalu Medical, Inc. 

1525 Faraday Avenue, Suite 180 
 Carlsbad, CA 92008 

Dear _________________: 
 As Escrow Agent for both Nalu Medical,
Inc. (the “Company”), and the undersigned purchaser of stock of the Company (the “Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock
Purchase Agreement (the “Agreement”) between the Company and the undersigned, in accordance with the following instructions: 
 1.
In the event the Company and/or any assignee of the Company (referred to collectively for convenience herein as the “Company”) exercises the Company’s repurchase option set forth in the Agreement, the Company shall give to Purchaser
and you a written notice specifying the number of shares of stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company. Purchaser and the Company hereby irrevocably authorize and direct you
to close the transaction contemplated by such notice in accordance with the terms of said notice. 
 2. At the closing, you are directed
(a) to date the stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver the stock assignments, together with the certificate evidencing the shares of stock to
be transferred, to the Company or its assignee, against the simultaneous delivery to you of the purchase price (by cash, a check, or some combination thereof) for the number of shares of stock being purchased pursuant to the exercise of the
Company’s repurchase option. 
 3. Purchaser irrevocably authorizes the Company to deposit with you any certificates evidencing shares
of stock to be held by you hereunder and any additions and substitutions to said shares as defined in the Agreement. Purchaser does hereby irrevocably constitute and appoint you as Purchaser’s attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities negotiable and to complete any transaction
herein contemplated, including but not limited to the filing with any applicable state blue sky authority of any required applications for consent to, or notice of transfer of, the securities. Subject to the provisions of this paragraph 3,
Purchaser shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you. 
 4. Upon written
request of the Purchaser, but no more than once per calendar year, unless the Company’s repurchase option has been exercised, you shall deliver to Purchaser a certificate or certificates representing so many shares of stock as are not then
subject to the Company’s repurchase option. Within one hundred and twenty (120) days after cessation of 

 
Purchaser’s continuous employment by or services to the Company, or any parent or subsidiary of the Company, you shall deliver to Purchaser a certificate or certificates representing the
aggregate number of shares held or issued pursuant to the Agreement and not purchased by the Company or its assignees pursuant to exercise of the Company’s repurchase option. 

5. If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to
Purchaser, you shall deliver all of the same to Purchaser and shall be discharged of all further obligations hereunder. 
 6. Your duties
hereunder may be altered, amended, modified or revoked only by a writing signed by all of the parties hereto. 
 7. You shall be obligated
only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by
the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Purchaser while
acting in good faith, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good faith. 

8. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or
corporation, excepting only orders or process of courts of law and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree, you shall not
be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have
been entered without jurisdiction. 
 9. You shall not be liable in any respect on account of the identity, authorities or rights of the
parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 

10. You shall not be liable for the outlawing of any rights under the Statute of Limitations with respect to these Joint Escrow Instructions
or any documents deposited with you. 
 11. You shall be entitled to employ such legal counsel and other experts as you may deem necessary
properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. 

12. Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be an officer or agent of the Company or if you
shall resign by written notice to each party. In the event of any such termination, the Company shall appoint a successor Escrow Agent. 

13. If you reasonably require other or further instruments in connection with these Joint Escrow Instructions or obligations in respect
hereto, the necessary parties hereto shall join in furnishing such instruments. 

  
 -2- 

 14. It is understood and agreed that should any dispute arise with respect to the delivery
and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such disputes shall have been settled
either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty
whatsoever to institute or defend any such proceedings. 
 15. Any notice required or permitted hereunder shall be given in writing and
shall be deemed effectively given upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties thereunto entitled at the following
addresses or at such other addresses as a party may designate by ten (10) days’ advance written notice to each of the other parties hereto. 

16. By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint Escrow Instructions; you do not
become a party to the Agreement. 
 17. This instrument shall be binding upon and inure to the benefit of the parties hereto, and their
respective successors and permitted assigns. 
 18. These Joint Escrow Instructions shall be governed by the internal substantive laws, but
not the choice of law rules, of California. 
  

							
	PURCHASER	 		 	NALU MEDICAL, INC.
				
		 		 		 	
	  
 Signature

 
	 		 	  
 By

 

	  
 Print Name

 
	 		 	  
 Print Name

 

	  
  
	 		 	  
 Title

 

	  
 Residence Address
	 		 	

  

			
	ESCROW AGENT

			
		
		 	
	  
 Corporate
Secretary

			
		
	Dated:	 	  

  
 -3- 

 EXHIBIT C-4 

ELECTION UNDER SECTION 83(b) 

OF THE INTERNAL REVENUE CODE OF 1986 
 The
undersigned taxpayer hereby elects, pursuant to Sections 55 and 83(b) of the Internal Revenue Code of 1986, as amended, to include in taxpayer’s gross income or alternative minimum taxable income, as the case may be, for the current taxable
year the amount of any compensation taxable to taxpayer in connection with taxpayer’s receipt of the property described below. 
  

	1.	 The name, address, taxpayer identification number and taxable year of the undersigned are as follows:

  

									
		 		  	TAXPAYER	    	SPOUSE	  	
		 	NAME:	  	  
	    	  
	  	
		 	ADDRESS:	  	  
	    	  
	  	
		 		  	  
	    	  
	  	
		 	TAX ID NO.:	  	  
	    	  
	  	
		 	TAXABLE YEAR:	  	                	    		  	

 2. The property with respect to which the election is made is described as follows: __________ shares (the
“Shares”) of the Common Stock of Nalu Medical, Inc. (the “Company”). 
  

	3.	 The date on which the property was transferred is:___________________ ,______. 

 

	4.	 The property is subject to the following restrictions: 

The Shares may not be transferred and are subject to forfeiture under the terms of an agreement between the taxpayer and the Company. These
restrictions lapse upon the satisfaction of certain conditions contained in such agreement. 
  

	5.	 The Fair Market Value at the time of transfer, determined without regard to any restriction other than a
restriction which by its terms shall never lapse, of such property is: $_________________. 

  

	6.	 The amount (if any) paid for such property is: $_________________. 

The undersigned has submitted a copy of this statement to the person for whom the services were performed in connection with the undersigned’s receipt of
the above-described property. The transferee of such property is the person performing the services in connection with the transfer of said property. 

The undersigned understands that the foregoing election may not be revoked except with the consent of the Commissioner. 

 

							
	Dated: ______________________, _____	 		 	
		 		 		 	  
 Taxpayer

 The undersigned spouse of taxpayer joins in this election. 

 

							
	Dated: ______________________, _____	 		 	
		 		 		 	  
 Spouse of Taxpayer

 EXHIBIT D 

JOINDER AGREEMENT 

WHEREAS, Nalu Medical, Inc. (the “Company”) previously granted the undersigned (the “Exercising Participant”) a stock
option (the “Option”) to purchase shares of the Company’s common stock (“Common Stock”) under the Company’s 2014 Equity Incentive Plan and subject to the terms and conditions of a Stock Option Agreement (the “Stock
Option Agreement”). 
 WHEREAS, the Exercising Participant now wishes to exercise the Option in accordance with the terms of the Stock
Option Agreement. 
 NOW, THEREFORE, by execution of this Joinder Agreement, the Exercising Participant hereby acknowledges and agrees as
follows: 
  

	 	6.	 The Exercising Participant hereby acknowledges receipt of the Company’s Amended and Restated Voting
Agreement dated June 26, 2015 by and among the Company and the stockholders listed on Exhibits A and B thereto, as may be amended from time to time (the “Voting Agreement”) and represents to the Company that he or she has read and
fully understands such Voting Agreement. 

  

	 	7.	 The Exercising Participant (i) has had an opportunity to consult with counsel and other advisors before
entering into this Joinder Agreement, (ii) hereby adopts and agrees to be bound by Section 3.1 of the Voting Agreement as a Common Holder (as defined in the Voting Agreement), and (iii) authorizes the Company to attach this executed
Joinder Agreement to the Voting Agreement, and to take such other actions as may be necessary or desirable to bind the Exercising Participant to such provisions. 

 

	 	8.	 The Exercising Participant has all requisite power and authority to enter into this Joinder Agreement and to
carry out his or her obligations hereunder. 

  

	 	9.	 All notices provided to the Exercising Participant shall be sent or delivered to the following address:

  

			
	
	  

	
	  

			
		
	Facsimile:	 	  

			
		
	e-mail:	 	  

  

	 	10.	 Governing Law. This Joinder Agreement shall be governed by and construed in accordance with the laws of
the State of Delaware applicable to contracts made and to be performed entirely within such state. 

 IN WITNESS WHEREOF, the Exercising Participant has executed and delivered this Joinder
Agreement. 
  

							
	EXERCISING PARTICIPANT	    		 	NALU MEDICAL, INC.
				
		    		 		 	
	  
 Signature

 
	    		 	  
 By

 

	  
 Print Name

 
	    		 	  
 Print Name

 

	  
  
	    		 	  
 Title

 

	  
 Residence Address

 
	    		 	
	  
 Email Address

 
	    		 	
	Dated:                                     
                                         
                       ,             	    		 	

  
 -2-EX-10.7

 Exhibit 10.7 

[***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively
harmful if publicly disclosed. 
 AMENDED AND RESTATED PATENT LICENSE AGREEMENT 

This AMENDED AND RESTATED PATENT LICENSE AGREEMENT (this “Agreement”) is made effective as of June 26, 2015 (the
“Effective Date”) by and between Nalu Medical, Inc., a Delaware corporation (“Nalu”) and AcceleMed, LLC, a Delaware limited liability company (“AcceleMed”). AcceleMed and Nalu are each
referred to herein as such or, individually, as a “Party” or, collectively, as the “Parties.” 

BACKGROUND 
  

	 	A.	 AcceleMed owns or has rights to AcceleMed Assigned Patents (as defined below); and AcceleMed desires to assign
such AcceleMed Assigned Patents to Nalu; and 

  

	 	B.	 AcceleMed also desires to grant to Nalu an exclusive license under certain AcceleMed Licensed Patents, and Nalu
desires to obtain such exclusive license, all on the terms and conditions set forth herein; and Nalu desires to grant to AcceleMed an exclusive license under certain Nalu Improvement Patents, and AcceleMed desires to obtain such exclusive license,
all on the terms and conditions set forth herein; and 

  

	 	C.	 The Parties entered into that certain Patent License Agreement dated November 7, 2014 (the
“Original License Agreement”) and the Parties now desire to amend and replace the Original License Agreement in its entirety with this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements provided herein below and other consideration, the receipt and
sufficiency of which is hereby acknowledged, AcceleMed and Nalu hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 The
following capitalized terms shall have the following meanings as used in this Agreement: 
 1.1 “AcceleMed Assigned Patents”
shall mean the patents and patent applications listed in Exhibit A hereto and all Patents claiming priority thereto or common priority therewith (the “Listed Assigned Patents”), together with any AcceleMed Improvement Patents owned
by AcceleMed. 
 1.2 “AcceleMed Field” shall mean all uses and applications other than Nalu Field. 

1.3 “AcceleMed Improvement Patents” shall mean any and all Patents Controlled by AcceleMed that claim Improvements that are
conceived and reduced to practice, or otherwise acquired during the Capture Period. 
 1.4 “AcceleMed Licensed Patents”
shall mean all AcceleMed Improvement Patents other than the AcceleMed Assigned Patents and the Stanford Patents. 

  
 1 

 1.5 “AcceleMed Licensed Product” shall mean any product, the manufacture,
sale, offer for sale, use or importation of which would, but for the licenses granted to AcceleMed herein, infringe any claim within the Nalu Improvement Patents or the AcceleMed Assigned Patents. 

1.6 “Affiliate” shall mean with respect to either Party, any Person controlling, controlled by or under common control with
such Party, for so long as such control exists. For purposes of this Section 1.6, “control” shall mean (i) direct or indirect ownership of more than 50% (or, if 50% or less, the maximum ownership interest permitted by applicable
law) of the stock or shares having the right to vote for the election of directors of such corporate entity or (ii) the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such
entity, whether through the ownership of voting securities, by contract or otherwise. Notwithstanding the foregoing, for purposes of this Agreement, neither Party nor any of its Affiliates shall be deemed an Affiliate of the other Party. 

1.7 “Capture Period” shall mean the period commencing on the Effective Date and continuing until the earliest of (i) a
Change of Control of Nalu, (ii) the termination of this Agreement, or (iii) the expiration of this Agreement. 
 1.8
“Change of Control” means, with respect to a Party, either: (i) the acquisition of such Party by a Third Party by means of any transaction or series of related transactions (including, without limitation, any reorganization,
merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the purpose of changing the domicile of such Party and excluding any sale of stock for capital raising purposes), unless the holders of the voting
power of such Party immediately prior to such transaction or series of related transactions hold, immediately after such transaction or series of related transactions, at least 50% of the voting power of the surviving or resulting entity (or if the
Party or such other surviving or resulting entity is a wholly-owned subsidiary immediately following such acquisition, its parent); or (ii) a sale, lease or other disposition of all or substantially all of the assets of such Party to a Third
Party by means of any transaction or series of related transactions, except where such sale, lease or other disposition is to a wholly-owned subsidiary of such Party. Notwithstanding the foregoing, in no event shall a sale by such Party of capital
stock (whether voting or otherwise) in any offering made pursuant to an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended, covering the offer and sale of such capital
stock, or any foreign equivalent thereof, constitute a Change of Control of such Party. 
 1.9 “Control” shall mean, with
respect to any Patent or Know-How, possession of the ability (other than pursuant to this Agreement), whether arising by ownership, license, or other authorization, to grant a license or sublicense without
violating the terms of any agreement or other arrangement with any Third Party; provided that, with respect to any Patent or Know-How first licensed or acquired from a Third Party after the Effective Date, if
the grant or exercise of the right(s) and license(s) granted hereunder under such Patent or Know-How requires any amount to be paid or become payable to a Third Party, such Patent or Know-How shall be deemed to be Controlled only to the extent that the Party obtaining such right or license agrees to reimburse the other party for such amounts and be bound by any other terms and/or conditions
required by the agreement pursuant to which the other Party first licensed or acquired such 

  
 2 

 
particular Patent or Know-How. “Controlled” and “Controlling” shall have their correlative meanings. 

1.10 “Improvement” shall mean any invention comprising or otherwise relating to (a) any invention described in the
Listed Assigned Patents (the “Inventions”), (b) any method or process of using or making an Invention, including without limitation any clinical, therapeutic, diagnostic or preventative use, (c) any apparatus or device attached
to an Invention or intended for use with an Invention, (d) any system that includes an Invention as a component, or (e) any method or process of using or making an apparatus, device or system described in (c) or (d), respectively.

 1.11 “In-License Agreement” means (a) any written agreement between Nalu or
its Affiliate and a Third Party pursuant to which Nalu or such Affiliate acquired or acquires Control of any Nalu Improvement Patents or (b) any written agreement between AcceleMed or its Affiliate and a Third Party pursuant to which AcceleMed
or such Affiliate acquired or acquires Control of any AcceleMed Licensed Patents. 
 1.12 “Nalu Licensed Product” shall
mean any product, the manufacture, sale, offer for sale, use or importation of which would, but for the licenses granted to Nalu herein, infringe any claim within the AcceleMed Licensed Patents. 

1.13 “Nalu Field” shall mean the treatment or management of (a) neuropathic pain, including but not limited to spinal
cord stimulation for pain, peripheral neuropathic pain, diabetic neuropathy, occipital pain and pelvic pain and (b) disease of the bladder and urinary tract, including but not limited to, overactive bladder and treatment of peripheral nerves
for the treatment of urinary incontinence disorders and all other known bladder diseases, (c) fecal incontinence and erectile dysfunction. The license specifically excludes treatments to the vagus nerve and vagus nerve bundle for any
indication. 
 1.14 “Nalu Improvement Patents” shall mean any and all Patents Controlled by Nalu that claim Improvements
that are conceived and reduced to practice, or otherwise acquired during the Capture Period. 
 1.15 “Patent” shall mean
any of the following, whether existing now or in the future anywhere in the world: (i) any issued patent, including any inventor’s certificate, utility model, substitution, extension, confirmation, reissue,
re-examination, renewal or any like governmental grant for protection of inventions; and (ii) any pending application for any of the foregoing, including any continuation, divisional, substitution,
addition, continuation-in-part, provisional and converted provisional application. 

1.16 “Person” shall mean any individual, corporation, partnership, association, joint-stock company, trust, unincorporated
organization or government or political subdivision thereof. 
 1.17 “Prosecution and Maintenance” shall mean, with respect
to a Patent, the preparing, filing, prosecuting and maintenance of applications therefor, as well as re-examinations, reissues, requests for term extensions and the like with respect to such Patent, together
with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to such Patent. 

  
 3 

 1.18 “Qualified Financing” shall mean a transaction or series of
transactions in which a company receives gross proceeds of $2,000,000 through the sale of its securities or incurrence of any debt, with the principal purpose of raising capital. 

1.19 “Stanford Patents” shall mean all Patents licensed to AcceleMed by The Board of Trustees of the Leland Stanford Junior
University pursuant to that certain Exclusive (Equity) Agreement dated June 26, 2015 and sublicensed by AcceleMed to Nalu pursuant to that certain Sublicense Agreement dated June 26, 2015. 

1.20 “Third Party” shall mean any Person other than Nalu or AcceleMed, or their respective Affiliates. 

1.21 “Transmitter” shall mean any wireless technology for communication with implanted medical devices. 

ARTICLE 2 
 ASSIGNMENT
AND LICENSES 
 2.1 Assignment of AcceleMed Assigned Patents. Subject to the terms and conditions of this Agreement,
including the rights and licenses granted to AcceleMed herein, and in lieu of license origination fees or royalties, AcceleMed agrees to assign and hereby assigns to Nalu all of its right, title and interest in and to the AcceleMed Assigned Patents.
Accordingly, AcceleMed agrees to disclose to Nalu each AcceleMed Assigned Patent, and each AcceleMed Improvement Patent, within sixty (60) days of the disclosure thereof on the applicable disclosure form to the applicable internal individual at
Nalu responsible for administering internal inventions. AcceleMed will sign, execute and acknowledge (and/or cause to be signed, executed and acknowledged), without cost but at the expense of Nalu, any and all documents, and to perform such acts, as
may be necessary, useful or convenient for the purposes of perfecting the foregoing assignment of such AcceleMed Assigned Patents and to obtain, enforce and/or defend intellectual property rights, including copyright and patent rights, in any and
all countries with respect to such AcceleMed Assigned Patents. 
 2.2 Licenses to Nalu. 

(a) Subject to the terms and conditions of this Agreement (including Section 2.4), AcceleMed agrees to grant and hereby grants to Nalu a
perpetual, irrevocable, exclusive, worldwide, fully paid-up, royalty-free license under the AcceleMed Licensed Patents to: (i) make, have made, use, sell, offer for sale and import Nalu Licensed Products,
(ii) practice any method, process or procedure in connection with its exercise of the activities described in clause (i), and (iii) otherwise exploit the AcceleMed Licensed Patents, in each case solely in the Nalu Field. 

(b) Subject to Section 2.4, Nalu may grant and authorize sublicenses within the scope of the license granted to it under
Section 2.2(a). Any such sublicenses granted pursuant to this Section 2.2(b) shall be subordinate to the terms and conditions of this Agreement. Nalu shall promptly provide AcceleMed a copy of all sublicense agreements executed by Nalu.

 2.3 Licenses to AcceleMed. 

  
 4 

 (a) Subject to the terms and conditions of this Agreement (including Section 2.4), Nalu
hereby grants to AcceleMed a perpetual, irrevocable, exclusive, worldwide, fully paid-up, royalty-free license under the Nalu Improvement Patents and the AcceleMed Assigned Patents to: (i) make, have
made, use, sell, offer for sale and import AcceleMed Licensed Products, (ii) practice any method, process or procedure in connection with its exercise of the activities described in clause (i), and (iii) otherwise exploit the Nalu
Improvement Patents and the AcceleMed Assigned Patents, in each case solely in the AcceleMed Field. 
 (b) Subject to Section 2.4,
AcceleMed may grant and authorize sublicenses within the scope of the license granted to it under Section 2.3(a). Any such sublicenses granted pursuant to this Section 2.3(b) shall be subordinate to the terms and conditions of this
Agreement. AcceleMed shall promptly provide Nalu a copy of all sublicense agreements executed by AcceleMed. 
 2.4 In-License Agreements. 
 (a) General. The Parties hereby acknowledge that the AcceleMed
Licensed Patents and the Nalu Improvement Patents may include Patents to which the Party granting the license pursuant to Sections 2.2 or 2.3, as applicable, (such Party, the “Licensor”) to the other Party
(“Licensee”) has obtained Control to such Patent pursuant to an In-License Agreement (any such Patent, an “In-Licensed Patent”).
Notwithstanding anything herein to the contrary, the license granted to Licensee in Section 2.2 with respect to any In-Licensed Patents within the AcceleMed Licensed Patents and in Section 2.3 with
respect to any In-Licensed Patents within the Nalu Improvement Patents shall be subject to (i) Licensee’s election in writing to include such In-Licensed
Patents within such license and (ii) Licensee’s agreement to be subject to any and all applicable terms and conditions (including restrictions and limitations) of the applicable In-License Agreement,
including without limitation the pass through to Licensee of any royalties and additional payments resulting from the Licensee’s exercise of such license; provided that any such license fees shall be shared pro rata by the Parties and any
additional sublicensees under such In-License Agreements. 
 (b) Disclosure of New In-Licensed Patents. For each In-License Agreement pursuant to which a Licensor acquires Control of any Patent, Licensor shall provide to Licensee a written disclosure
describing in reasonable detail the Patents that are the subject thereof and all material terms and conditions of such In-License Agreement (including financial obligations) to the extent not previously
disclosed by Licensor to Licensee. Licensor shall provide such written disclosures to Licensee (i) no later than thirty (30) days after the execution In-License Agreement with respect to In-License Agreements executed after the Effective Date, and (ii) no later than thirty (30) days after the Effective Date with respect to In-License Agreements
executed prior to the Effective Date. All such disclosures shall be deemed to be the Confidential Information of Licensor. 
 (c)
Election to Obtain Sublicense. Within thirty (30) days of any disclosure given by Licensor pursuant to Section 2.4(b), Licensee shall elect whether or not to include such In-Licensed Patent in
the license granted pursuant to Section 2.2 or pursuant to Section 2.3, as applicable, by providing Licensor with written notice of its election. If no such notice is provided by Licensee pursuant to this Section 2.4(c) during such
thirty (30) day period, Licensee 

  
 5 

 
shall be deemed to have elected not to include such In-Licensed Patent within the scope of the license granted to it pursuant to Section 2.2 or 2.3,
as applicable. 
 (d) Modification, Waiver or Amendment. Licensor shall promptly notify Licensee of any proposed modification, waiver
or amendment of or to any provision of any In-License Agreement to which Licensor is a party, and shall consider in good faith any comments provided by Licensee relating thereto; provided, however, Licensor
shall not modify, waive or amend any provision of any In-License Agreement that materially restricts the licenses and rights granted to Licensee herein without Licensee’s prior consent, which consent
shall not be unreasonably withheld, conditioned or delayed. 
 (e) Licensor Obligations. With respect to each In-License Agreement from which In-Licensed Patents are included in the Nalu Improvement Patents or AcceleMed Licensed Patents, as applicable, Licensor shall have the right to
terminate such In-License Agreement without the prior consent of Licensee provided that the sublicense granted to Licensee thereunder survives such termination. Otherwise Licensor may terminate such In-License Agreement only with Licensee’s prior written consent, not to be unreasonably withheld, conditioned or delayed. In the event of any assignment of any In-License
Agreement, such assignment shall be subject to the rights and licenses granted to Licensee herein. Licensor will promptly notify Licensee of any notice of breach given or received under any In-License
Agreement, or of any dispute likely to give rise to such a notice, and shall cooperate with and afford Licensee the reasonable opportunity to cure such breach on behalf of Licensor, if so requested by Licensee. 

2.5 Know-How Transfer. 

(a) Promptly after the execution of this Agreement, AcceleMed will transfer to Nalu any technical information, materials, methods and/or other
know-how (collectively, “Know-How”) Controlled by AcceleMed that are necessary or useful for the practice of the AcceleMed Assigned Patents or the
AcceleMed Licensed Patents in the Nalu Field. During the Capture Period, AcceleMed agrees to promptly disclose to Nalu in reasonable detail any AcceleMed Improvement Patents, and transfer to Nalu any Know-How
Controlled by AcceleMed that is necessary or useful for the practice of any AcceleMed Improvement Patents in the Nalu Field. Nalu and its sublicensees shall have the right to use Know-How described in this
Section 2.5(a) in connection with the practice of AcceleMed Licensed Patents and AcceleMed Improvement Patents solely in the Nalu Field. 

(b) Promptly after the execution of this Agreement, Nalu will transfer to AcceleMed any Know-How
Controlled by Nalu that are necessary or useful in the practice of the AcceleMed Assigned Patents or the AcceleMed Licensed Patents in the AcceleMed Field. During the Capture Period, Nalu shall promptly disclose and transfer to AcceleMed any Know-How Controlled by Nalu that is necessary or useful for the practice of any Nalu Improvement Patents or AcceleMed Assigned Patents in the AcceleMed Field. AcceleMed and its sublicensees shall have the right to
use Know-How described in this Section 2.5(b) in connection with the practice of AcceleMed Licensed Patents and Nalu Improvement Patents solely in the AcceleMed Field. 

2.6 Retention of Rights. AcceleMed shall retain all rights in and to the AcceleMed Licensed Patents and AcceleMed Improvement Patents
for all uses in the AcceleMed Field. No 

  
 6 

 
rights are granted to Nalu by this Agreement, except as expressly provided herein 

ARTICLE 3 

CONSIDERATION 
 3.1
License Fee. In consideration of the rights and licenses granted by AcceleMed hereunder, Nalu shall issue shares of Nalu common stock as follows: 

[***]  

3.2 Payments. All payments due under this Agreement to AcceleMed shall be made by bank wire transfer in immediately available funds to
an account designated by AcceleMed. All payments hereunder shall be made in the legal currency of the United States of America, and all references to “$” or “dollars” shall refer to United States dollars. 

ARTICLE 4 
 DILIGENCE

 Nalu shall use commercially reasonable efforts to develop and sell Nalu Licensed Products. Additionally, after the first commercial sale of Nalu
Licensed Products hereunder, Nalu shall use its commercially reasonable efforts to meet the market demand for such Nalu Licensed Products; provided, however, that the foregoing shall not be construed to constrain or otherwise limit Nalu’s
pricing or product strategy for Nalu Licensed Products, which shall be in Nalu’s sole discretion. 
 ARTICLE 5 

PROSECUTION AND ENFORCEMENT 

5.1 Prosecution by Nalu. As between the Parties, Nalu shall be responsible for and control the Prosecution and Maintenance of the
AcceleMed Assigned Patents, AcceleMed Licensed Patents and Nalu Improvement Patents at its own expense; provided that the foregoing shall be subject to the terms and conditions of an applicable In-License
Agreements. In addition, upon AcceleMed’s request, Nalu shall be obligated to Prosecute and Maintain at AcceleMed’s expense continuations of the AcceleMed Assigned Patents, AcceleMed Licensed Patents and Nalu Improvement Patents with
claims limited to the AcceleMed Field (“AcceleMed Continuations”); provided, however, that if Nalu declines to Prosecute and Maintain any AcceleMed Continuation following AcceleMed’s request, AcceleMed shall have the right to
Prosecute and Maintain such AcceleMed Continuation itself. AcceleMed shall cooperate with and assist Nalu in connection with the Prosecution and Maintenance of the AcceleMed Assigned Patents, AcceleMed Licensed Patents and Nalu Improvement Patents.
Nalu shall keep AcceleMed reasonably informed as to the status of the AcceleMed Assigned Patents, AcceleMed Licensed Patents and Nalu Improvement Patents, and shall consult with AcceleMed in a timely manner, provide AcceleMed reasonable opportunity
to review and comment, and consider in good faith any comments provided by AcceleMed concerning (i) the scope and content of patent applications within the AcceleMed Assigned Patents, AcceleMed Licensed Patents and Nalu Improvement
Patents prior to filing such patent applications, and (ii) the content of and proposed responses to official actions of the United States Patent and Trademark Office and foreign patent offices during prosecution of such patent
applications. Additionally, in the event Nalu decides to abandon any Patent within the AcceleMed Assigned Patents, AcceleMed Licensed Patents or 

  
 7 

 
Nalu Improvement Patents (each, a “Proposed Abandoned Patent”), Nalu shall notify AcceleMed thereof at least ninety (90) days in advance of any required action related to
the Prosecution and Maintenance of such Patent and AcceleMed shall have the right, but not the obligation, to undertake Prosecution and Maintenance of such Proposed Abandoned Patent(s). 

5.2 Reimbursement of Patent Expenses. Nalu shall be solely responsible for Prosecution and Maintenance expenses for the AcceleMed
Assigned Patents, AcceleMed Licensed Patents and AcceleMed Improvement Patents, provided AcceleMed agrees to reimburse Nalu for the expenses incurred by Nalu with respect to Prosecution and Maintenance of AcceleMed Continuations, solely to the
extent such Prosecution and Maintenance has been requested by AcceleMed. 
 5.3 Enforcement Rights. 

(a) Notification of Infringement. If either Party learns of any infringement or threatened infringement of (i) any Patent within the
AcceleMed Assigned Patents, AcceleMed Licensed Patents and AcceleMed Improvement Patents by the manufacture, use, development or commercialization of a product or service by a Third Party solely in the Nalu Field (each, a “Nalu Infringement
Claim”), (ii) any Patent within the AcceleMed Assigned Patents, AcceleMed Licensed Patents and AcceleMed Improvement Patents by the manufacture, use, development or commercialization of a product or service by a Third Party solely in the
AcceleMed Field (each, a “AcceleMed Infringement Claim”), or (iii) any Patent within the AcceleMed Assigned Patents, AcceleMed Licensed Patents and AcceleMed Improvement Patents by the manufacture, use, development or
commercialization of a product or service by a Third Party in both Nalu Field and AcceleMed Field (each, a “General Infringement Claim”), such Party shall promptly notify the other Party describing such infringement. Subject to this
Section 5.3, the Parties shall discuss such infringement and appropriate steps to be taken with regard to such infringement and shall share available evidence thereof. As between the Parties, the right to enforce such Patent with respect to such
infringement, or to defend any declaratory judgment action with respect thereto (each, an “Enforcement Action”) shall be as set forth in Section 5.3(b). 

(b) Enforcement. 
 (1)
Nalu Infringement Claim. Except to the extent otherwise agreed by the Parties, as between the Parties, Nalu (or its designee) shall have the first right, but not the obligation, to institute, prosecute and control any Enforcement Action with
respect to each Nalu Infringement Claim, at its sole expense. If Nalu (or its designee) fails to initiate an Enforcement Action with respect to a Nalu Infringement Claim within 120 days after a request by AcceleMed to do so, then AcceleMed shall
have the right, upon notice to Nalu, to institute, prosecute and control such Enforcement Action, at its sole expense (subject to reimbursement as set forth below). 

(2) AcceleMed Infringement Claim. Except to the extent otherwise agreed by the Parties, as between the Parties, AcceleMed (or its
designee) shall have the sole right, but not the obligation, to institute, prosecute and control any Enforcement Action with respect to each AcceleMed Infringement Claim, at its sole expense. If AcceleMed (or its designee) fails to initiate an
Enforcement Action with respect to such AcceleMed Infringement Claim within 120 days after a request by Nalu to do so, then Nalu shall have the right, upon notice to AcceleMed, 

  
 8 

 
to institute, prosecute and control such Enforcement Action, at its sole expense (subject to reimbursement as set forth below). 

(3) General Infringement Claim. In the event there is any General Infringement Claim, the Parties shall discuss the appropriate steps
to be taken with regard to such infringement, including the appropriate Enforcement Action to be taken, the control of such Enforcement Action, and the allocation of damages or other monetary awards received therefrom. 

(c) Cooperation; Recoveries. 

(1) If a Party (the “Controlling Party”) brings any Enforcement Action pursuant to Section 5.3(b), then the other Party
(the “Cooperating Party”) shall cooperate as reasonably requested, at such Controlling Party’s expense, in the pursuit of such Enforcement Action, including by joining as a party to any such Enforcement Action if it is a
necessary or indispensable party or taking such other actions as are necessary for standing or for the Controlling Party to otherwise maintain or pursue the Enforcement Action. The Controlling Party for an Enforcement Action shall: (i) have the
right to use counsel of its choice in such Enforcement Action, (provided that the Cooperating Party shall have the right, even if not required to be joined, to participate in such Enforcement Action with its own counsel, at its own expense), (ii)
keep the Cooperating Party reasonably informed with respect to the progress or disposition of such Enforcement Action, including reasonable consultation regarding any settlements, and (iii) use reasonable efforts to avoid and minimize any
potential adverse impact on the Cooperating Party’s rights and interests. Neither Party shall have the right to make any admission or settle any Enforcement Action under this Section 5.3 in a manner that admits the invalidity or
unenforceability of the other Party’s Patents without the prior written consent of the other Party, which shall not be unreasonably withheld. The Controlling Party for an Enforcement Action shall also have the right to control the settlement of
such Enforcement Action; provided, however, no settlement shall be entered into without the consent of the Cooperating Party if such settlement would materially and adversely affect the interests of the Cooperating Party. 

(2) Any damages or other monetary awards recovered from the settlement of or judgment from an Enforcement Action shall be allocated first to
reimburse the Controlling Party for the costs and expenses incurred by it in connection with such Enforcement Action (including any expenses or costs incurred by the Controlling Party to reimburse the Cooperating Party pursuant to
Section 5.3(c)(1)), and then to reimburse the Cooperating Party for the costs and expenses incurred by it in connection with such Enforcement Action to the extent not previously reimbursed. Any amounts remaining shall be shared seventy-five
percent (75%) to the Controlling Party and twenty-five percent (25%) to the Cooperating Party. 
 ARTICLE 6 

CONFIDENTIALITY 

6.1 Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the
Parties agree that a Party receiving (the “Receiving Party”) any confidential or proprietary information and materials furnished to it by the other Party (the “Disclosing Party”) pursuant to this Agreement
(collectively, “Confidential Information”) shall keep confidential and shall not publish or otherwise disclose or use for any 

  
 9 

 
purpose other than as provided for in this Agreement, except to the extent that it can be established by written documentation by the Receiving Party that such Confidential Information: 

(a) was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure; 

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or
omission of the Receiving Party in breach of this Agreement; 
 (d) was independently developed by the Receiving Party as demonstrated by
documented evidence prepared contemporaneously with such independent development; or 
 (e) was disclosed to the Receiving Party, other than
under an obligation of confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others. 

6.2 Authorized Disclosure. Except as expressly provided otherwise in this Agreement, the Receiving Party may use and disclose
Confidential Information of the Disclosing Party as follows: (i) under appropriate confidentiality provisions substantially equivalent to those in this Agreement, in connection with the performance of its obligations or exercise of
rights granted or reserved in this Agreement (including the right grant licenses and sublicenses hereunder); (ii) to the extent such disclosure is reasonably necessary in filing or prosecuting Patent, copyright and trademark applications, complying
with the terms of agreements with third parties in existence as of the Effective Date or thereafter pursuant to which the Receiving Party first obtains rights to Patents licensed hereunder, prosecuting or defending litigation, complying with
applicable governmental regulations, obtaining regulatory approvals, marketing products, or otherwise required by law, provided, however, that if a Receiving Party is required by law to make any such disclosure of a Disclosing Party’s
Confidential Information it will, except where impracticable for exigent disclosures (for example, in the event of medical emergency), give reasonable advance notice to the Disclosing Party of such disclosure requirement and, except to the extent
inappropriate in the case of patent applications, will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed; (iii) in communication with existing and potential investors,
acquirers, consultants, advisors (including attorneys and accountants) or others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or (iv) to the
extent mutually agreed to by the Parties. 
 6.3 Confidential Terms. Each of the Parties agrees not to disclose to any Third Party
the terms and conditions of this Agreement without the prior approval of the other Party, except: (i) to potential investors, acquirers, consultants, advisors (including attorneys and accountants) or others on a need to know basis, in each
case under circumstances that reasonably ensure the confidentiality thereof; or (ii) under circumstances that reasonably ensure the confidentiality of the information, to the extent necessary (A) to comply with the terms of
agreements with third parties or (B) in connection with the performance of its obligations or exercise of rights granted or reserved in this Agreement (including the right to grant licenses and sublicenses hereunder);

  
 10 

 
or (iii) to the extent required by applicable law, provided, however, that if a Party is required by law to make any such disclosure of the terms or conditions of this Agreement, it will
give reasonable advance notice to the other Party of such disclosure requirement and will use its reasonable efforts to seek confidential treatment of such terms and conditions. 

ARTICLE 7 

REPRESENTATIONS AND WARRANTIES 

7.1 Mutual Representations. Each Party hereby represents and warrants to the other Party that: (i) it has the legal power,
authority and right to enter into this Agreement and to perform all of its obligations hereunder; (ii) it has the right and power to grant the rights and licenses granted by it hereunder; (iii) it has not previously granted,
and will not grant, any rights which are in conflict with the rights and licenses granted to the other Party herein; (iv) as of the Effective Date, the intellectual property rights assigned or licensed by it to the other Party herein are
free and clear of any lien, charges, encumbrances and security interests; and (v) to the best of its knowledge as of the Effective Date, there are no threatened or pending actions, suits, investigations, claims or proceedings in any way
relating to the intellectual property rights assigned or licensed by it to the other Party herein. AcceleMed represents and warrants to Nalu that, as of the Effective Date, it holds the entire right, title and interest in and to the Patents listed
on Exhibit A free and clear of all liens. 
 7.2 Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 7, NEITHER PARTY MAKES ANY
REPRESENTATIONS, WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER HEREOF, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, AND NON-INFRINGEMENT.  
 ARTICLE 8 

INDEMNIFICATION 

8.1 Indemnification of AcceleMed. Subject to Section 8.3, Nalu shall indemnify, defend and hold AcceleMed and its
respective directors, officers, employees, agents (collectively, the “AcceleMed Indemnitees”) harmless from and against any and all liabilities, losses, costs, damages, fees or expenses (including reasonable legal expenses and
attorneys’ fees) payable to a Third Party (collectively, “Losses”) incurred by any AcceleMed Indemnitee as a result of any claim, demand, action or suit brought by a Third Party against an AcceleMed Indemnitee to the extent
arising out of or related to: (i) the exercise or the practice by or under authority of Nalu of the rights or licenses granted to Nalu hereunder, including product liability claims; or (ii) Nalu’s breach of Nalu’s
express representations and warranties set forth herein. Notwithstanding the foregoing, Nalu’s obligation to indemnify under this Section 8.1 shall not extend to Losses for which AcceleMed is obligated to indemnify Nalu pursuant to
Section 8.2 below. 
 8.2 Indemnification of Nalu. Subject to Section 8.3, AcceleMed shall indemnify, defend
and hold Nalu and its respective directors, officers, employees, agents (collectively, the “Nalu Indemnitees”) harmless from and against any and all Losses incurred by any Nalu 

  
 11 

 
Indemnitee as a result of any claim, demand, action or suit brought by a Third Party against a Nalu Indemnitee to the extent arising out of or related to: (i) the exercise or the practice by
or under authority of AcceleMed of the rights or licenses granted to AcceleMed hereunder, including product liability claims; or (ii) AcceleMed’s breach of AcceleMed’s express representations and warranties set forth herein.
Notwithstanding the foregoing, AcceleMed’s obligation to indemnify under this Section 8.2 shall not extend to Losses for which Nalu is obligated to indemnity AcceleMed pursuant to Section 8.1 above. 

8.3 Claim for Indemnification. Whenever any claim shall arise for indemnification under this Article 8, the Party entitled to
indemnification hereunder (the “Indemnified Party”) shall promptly notify the Party from which it is seeking indemnification (the “Indemnifying Party”) of the claim and, when known, the facts constituting the basis
for the claim. The Indemnifying Party may, upon notice to the Indemnified Party, assume defense thereof at its own expense. The Indemnified Party shall not settle or compromise any claim for which it is entitled to indemnification without the prior
consent of the Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed. In no event shall Indemnifying Party settle any claim without the prior consent of the Indemnified Party if such settlement does not include
a release from liability on such claim or if such settlement would involve undertaking an obligation other than the payment of money that would bind or impair the Indemnified Party. 

ARTICLE 9 
 TERM AND
TERMINATION 
 9.1 Term. Unless earlier terminated pursuant to a provision of this Article 9, this Agreement shall be deemed
effective as of the Effective Date and shall continue in full force and effect until the expiration, revocation, invalidation of the last patent or the abandonment of the last patent application within the AcceleMed Licensed Patents, whichever is
later. 
 9.2 In the Event of Breach. In the event of a material breach by either Party of a material provision hereof, which breach
is not cured within sixty (60) days after written notice thereof by the other Party (“Cure Period”), then the Parties agree to resolve any damages through the use of arbitration in accordance with Section 10.2. The Cure
Period may be extended by written mutual agreement of AcceleMed and Nalu. 
 9.3 General Effects of Expiration or Termination.
Expiration or termination of this Agreement for any reason shall not release either Party hereto from any liability that at the time of such termination or expiration has already accrued to the other Party. Upon the expiration or any termination of
this Agreement, (i) the provisions of Articles 1-10 shall survive, and (ii) any sublicenses granted by a Party in accordance with this Agreement shall survive, provided that the applicable
sublicensee agrees in writing to be bound by the applicable terms of this Agreement. Except as otherwise expressly provided in this Article 9, all other terms and conditions of this Agreement shall terminate upon expiration or termination of this
Agreement. 
 ARTICLE 10 

GENERAL 
 10.1
Governing Law. This agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of California, United States of America, without reference to principles of conflicts of law. 

  
 12 

 10.2 Arbitration. The Parties agree that any dispute or controversy arising out of,
in relation to, or in connection with this Agreement, or the making, interpretation, construction, performance or breach hereof, shall be finally settled by binding arbitration in San Francisco, California under the then current rules of the
Judicial Arbitration and Mediation Services (JAMS) by one (1) arbitrator appointed in accordance with such rules. The arbitrator may grant injunctive or other relief in such dispute or controversy. The decision of the arbitrator shall be final,
conclusive and binding on the Parties to the arbitration. Judgment may be entered on the arbitrator’s decision in any court of competent jurisdiction. The Parties agree that, any provision of applicable law notwithstanding, they will not
request and the arbitrator shall have no authority to award, punitive or exemplary damages against either Party. The costs of the arbitration, including administrative and arbitrator’s fees, shall be shared equally by the Parties. Each Party
shall bear the cost of its own attorneys’ fees and expert witness fees. Nothing in this Section 10.2 shall preclude either Party from seeking interim or provisional relief in the form of a temporary restraining order, preliminary
injunction, or other interim relief concerning a dispute prior to or during an arbitration pursuant to this Section 10.2 necessary to protect the interests of such Party. 

10.3 Assignment. This Agreement may not be assigned by either Party without the prior written consent of the other Party.
Notwithstanding the foregoing, either Party may, without such consent, assign this Agreement and its rights, obligations and interests, in whole or in part, to any of its Affiliates or to a Third Party that succeeds to all or substantially all of
its business or assets relating to this Agreement whether by sale, merger, operation of law or otherwise. For clarity, each Party may exercise its rights and/or perform its obligations under this Agreement through one or more of its Affiliates. 

10.4 Consequences of Bankruptcy. The Parties acknowledge and agree that all rights and licenses now or hereafter granted under or
pursuant to any Section of this Agreement are rights to “intellectual property” as defined in Section 101(35A) of Title 11 of the United States Code. Each Party may elect to retain and may fully exercise all of its rights and
elections under Section 365(n) of Title 11 of the United States Code. 
 10.5 Force Majeure. In the event either Party hereto is
prevented from or delayed in the performance of any of its obligations hereunder by reason of acts of God, war, strikes, riots, storms, fires, earthquake, power shortage or failure, failure of the transportation system, or any other cause whatsoever
beyond the reasonable control of the Party (“Force Majeure Event”), the Party so prevented or delayed shall be excused from the performance of any such obligation during a period that is reasonable in light of the Force Majeure
Event, but no less than the duration of the Force Majeure Event itself. 
 10.6 Notices. Any notice, request, delivery, approval or
consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified) or by express courier service (signature
required) or five days after it was sent by registered letter, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two days after such mailing, to the Party
to which it is directed at its address or facsimile number shown below or such other address or facsimile number as such Party will have last given by notice to the other Party. 

  
 13 

 If to AcceleMed: [***] 

If to Nalu: [***] 
 10.7 No Waiver. A
waiver, express or implied, by either AcceleMed or Nalu of any right under this Agreement or of any failure to perform or breach hereof by the other Party hereto shall not constitute or be deemed to be a waiver of any other right hereunder or of any
other failure to perform or breach hereof by such other Party, whether of a similar or dissimilar nature thereto. 
 10.8 Limitation of
Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY, INCIDENTAL, STATUTORY OR PUNITIVE DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM
RELATING TO THIS AGREEMENT, OR THE SUBJECT MATTER HEREOF, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

10.9 Severability. If any provision of this Agreement shall be found by a court to be void, invalid or unenforceable, the same shall be
reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of the remainder of this Agreement, and the remainder of the Agreement shall remain in full force and effect. 

10.10 Interpretation. All headings are inserted for convenience of reference only and shall not affect its meaning or interpretation.

 10.11 Entire Agreement. This Agreement constitutes the entire understanding and agreement between the Parties with respect to the
subject matter hereof and supersedes any and all prior and contemporaneous negotiations, representations, agreements, and understandings, written or oral, that the Parties may have reached with respect to the subject matter hereof, including the
Original License Agreement. No agreements altering or supplementing the terms hereof may be made except by means of a written document signed by the duly authorized representatives of each of the Parties hereto. 

10.12 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but both of which
together shall constitute one and the same instrument. This Agreement may be executed through electronic (including .pdf) or facsimile transmitted signature. 

  
 14 

 IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their
duly authorized representatives as of the Effective Date. 
  

									
	ACCELEMED, LLC	 		 	NALU MEDICAL, INC.
					
	By:	 	/s/ Michael Partsch	 		 	By:	 	/s/ Keegan Harper
					
	Name:	 	Michael Partsch	 		 	Name:	 	Keegan Harper
					
	Title:	 	Managing Member	 		 	Title:	 	President and Chief Executive Officer
					
	Date:	 	 	 		 	Date:	 	 

  
 15 

 Exhibit A 

Licensed Patents 
  

									
	Serial #	  	Patent #	  	Publication #	  	Title	  	Inventors
	 61/953,702
	  		  		  	 METHOD AND APPARATUS FOR VERSATILE MINIMALLY INVASIVE NEUROMODULATORS
	  	 <TBD>

					
	 PCT/US2015/02080
	  		  	Filed March 16, 2015	  	 METHOD AND APPARATUS FOR VERSATILE MINIMALLY INVASIVE NEUROMODULATORS
	  	 <TBD>

					
	 62/015,392
	  		  		  	 METHOD AND APPARATUS FOR NEUROMODULATION TREATMENTS OF PAIN AND OTHER CONDITIONS
	  	 <TBD>

					
	 62/530,085
	  		  		  	 METHOD AND APPARATUS FOR OPERATION WITH MINIMALLY INVASIVE NEUROMODULATORS
	  	 <TBD>

					
	 62/077,181
	  		  		  	 METHOD AND APPARATUS FOR IMPLANTABLE NEUROMODULATION SYSTEMS
	  	 <TBD>

					
	 62/112,858
	  		  		  	 MEDICAL APPARATUS INCLUDING AN IMPLANTABLE SYSTEM AND AN EXTERNAL SYSTEM
	  	 <TBD>

					
	 61/836,536
	  		  		  	 FOR MINIMALLY INVASIVE IMPLANTABLE MODULATORS
	  	 <TBD>

					
	 61/836,544
	  		  		  	 METHOD AND APPARATUS FOR MINIMALLY INVASIVE IMPLANTABLE MODULATORS
	  	 <TBD>

					
	 PCT/US2014/043023
	  		  	WO2014205129	  	 METHOD AND APPARATUS FOR MINIMALLY INVASIVE IMPLANTABLE MODULATORS
	  	 [***]

  
 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]